Electronic Theses and Dissertation

Respon pemberian proloterapi dekstrosa hipertonis pada pasien osteoatritis lutut terhadap kadar interleukin-1 beta (il-1β) sinovial dan kemampuan fungsional latar belakang: osteoartritis (oa) lutut merupakan penyakit degeneratif sendi yang menyebabkan nyeri, kekakuan, dan penurunan fungsi. sitokin proinflamasi seperti interleukin-1 beta (il-1β) berperan dalam proses inflamasi dan degradasi kartilago. proloterapi dekstrosa hipertonis 25% merupakan terapi injeksi yang berpotensi memperbaiki gejala melalui stimulasi penyembuhan jaringan dan modulasi inflamasi. tujuan: menilai respons pemberian proloterapi dekstrosa hipertonis 25% terhadap kadar il-1β dan kemampuan fungsional berdasarkan skor western ontario and mcmaster universities osteoarthritis index (womac) pada pasien oa lutut. metode: penelitian quasi eksperimen dengan desain pre–post (case series) dilakukan di poliklinik reumatologi rsud dr. zainoel abidin banda aceh pada juni–november 2025. subjek adalah pasien oa lutut usia ≥50 tahun grade ii–iii kellgren–lawrence. proloterapi dekstrosa hipertonis 25% diberikan pada minggu ke-1, ke-5, dan ke-9. kadar il-1β diambil dari cairan sendi lutut diukur menggunakan elisa, sedangkan womac dinilai sebelum dan setelah rangkaian terapi. analisis menggunakan uji wilcoxon signed rank test (p

RESPONSE TO ADMINISTRATION OF HYPERTONIC DEXTROSE PROLOTHERAPY IN KNEE OSTEOARTRITIS PATIENTS ON SYNOVIAL INTERLEUKIN-1 BETA LEVELS SYNOVIAL AND FUNCTIONAL ABILITY Background: Knee osteoarthritis (OA) is a degenerative joint disease characterized by pain, stiffness, and functional limitation. Pro-inflammatory cytokines such as interleukin-1 beta (IL-1β) contribute to inflammation and cartilage degradation. Twenty-five percent hypertonic dextrose prolotherapy is an injectable therapy that may improve symptoms by stimulating tissue repair and modulating inflammation. Objective: To evaluate the response of 25% hypertonic dextrose prolotherapy on Synovial IL-1β levels and functional ability assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) in patients with knee OA. Methods: A quasi-experimental time series study was conducted at the Rheumatology Outpatient Clinic of dr. Zainoel Abidin General Hospital, Banda Aceh, from June to November 2025. Participants were knee OA patients aged ≥50 years with Kellgren–Lawrence grade II–III. Prolotherapy (25% hypertonic dextrose) was administered at weeks 1, 5, and 9. Synovial fluid IL-1β was measured using ELISA. WOMAC scores were assessed before and after the treatment series. Data were analyzed using the Wilcoxon Signed Rank Test (p